{"id":360340,"date":"2025-08-30T14:06:13","date_gmt":"2025-08-30T14:06:13","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-keros-therapeutics\/"},"modified":"2025-08-30T14:06:13","modified_gmt":"2025-08-30T14:06:13","slug":"how-to-buy-keros-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/","title":{"rendered":"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334036,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-360340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Keros Therapeutics, Inc. (KROS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve KROS hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat\u0131, ticaret stratejilerini ke\u015ffedin ve bu biyoteknoloji hissesinin portf\u00f6y\u00fcn\u00fcz\u00fc nas\u0131l d\u00f6n\u00fc\u015ft\u00fcrebilece\u011fini anlay\u0131n.","description_source":{"label":"Description","type":"textarea","formatted_value":"Keros Therapeutics, Inc. (KROS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve KROS hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat\u0131, ticaret stratejilerini ke\u015ffedin ve bu biyoteknoloji hissesinin portf\u00f6y\u00fcn\u00fcz\u00fc nas\u0131l d\u00f6n\u00fc\u015ft\u00fcrebilece\u011fini anlay\u0131n."},"intro":"Portf\u00f6y\u00fcn\u00fcze biraz biyoteknoloji heyecan\u0131 katmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Keros Therapeutics (KROS), nadir hastal\u0131klara y\u00f6nelik \u00e7\u0131\u011f\u0131r a\u00e7an bilimle t\u0131bbi inovasyonun \u00f6n saflar\u0131n\u0131 temsil ediyor. Klinik a\u015famadaki bu \u015firket, \u00f6nemli bir b\u00fcy\u00fcme f\u0131rsat\u0131 olabilir, ancak benzersiz f\u0131rsatlar\u0131n\u0131 ve risklerini nas\u0131l y\u00f6netece\u011finizi anlaman\u0131z gerekiyor. Bu yat\u0131r\u0131m\u0131 sizin i\u00e7in nas\u0131l i\u015fe yarar hale getirece\u011finizi ad\u0131m ad\u0131m inceleyelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Portf\u00f6y\u00fcn\u00fcze biraz biyoteknoloji heyecan\u0131 katmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Keros Therapeutics (KROS), nadir hastal\u0131klara y\u00f6nelik \u00e7\u0131\u011f\u0131r a\u00e7an bilimle t\u0131bbi inovasyonun \u00f6n saflar\u0131n\u0131 temsil ediyor. Klinik a\u015famadaki bu \u015firket, \u00f6nemli bir b\u00fcy\u00fcme f\u0131rsat\u0131 olabilir, ancak benzersiz f\u0131rsatlar\u0131n\u0131 ve risklerini nas\u0131l y\u00f6netece\u011finizi anlaman\u0131z gerekiyor. Bu yat\u0131r\u0131m\u0131 sizin i\u00e7in nas\u0131l i\u015fe yarar hale getirece\u011finizi ad\u0131m ad\u0131m inceleyelim."},"body_html":"<h2>\ud83d\udcc8 Keros Therapeutics Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>30 A\u011fustos 2025 itibar\u0131yla Keros Therapeutics, Inc. (KROS) <strong>15,48 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu fiyat hem de\u011fer avc\u0131lar\u0131n\u0131n hem de b\u00fcy\u00fcme yat\u0131r\u0131mc\u0131lar\u0131n\u0131n dikkatini \u00e7ekti. Ancak takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong> kesinlikle kritik. Keros, bu tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve tarihsel olarak bu raporlar hisse fiyat\u0131nda \u00f6nemli hareketlere neden oldu.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 KROS Hissesini Nas\u0131l Hareket Ettirir<\/h3> <p>Biyoteknoloji hisseleri gibi KROS i\u00e7in kazan\u00e7lar\u0131n neden bu kadar \u00f6nemli oldu\u011funu g\u00f6stereyim:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>6 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>14,32 $<\/td><td>%8,1 Art\u0131\u015f (EPS tahminlerini a\u015ft\u0131)<\/td><\/tr> <tr><td>7 May 2025<\/td><td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>16,50 $<\/td><td>%12,3 D\u00fc\u015f\u00fc\u015f (gelir beklentisi kar\u015f\u0131lanmad\u0131)<\/td><\/tr> <tr><td>12 \u015eub 2025<\/td><td>Y\u0131ll\u0131k Rapor<\/td><td>18,75 $<\/td><td>%4,2 Art\u0131\u015f (pipeline ilerlemesi)<\/td><\/tr> <tr><td>5 Kas 2024<\/td><td>3. \u00c7eyrek 2024<\/td><td>20,10 $<\/td><td>%6,8 D\u00fc\u015f\u00fc\u015f (klinik gecikmeler)<\/td><\/tr> <tr><td>8 A\u011fu 2024<\/td><td>2. \u00c7eyrek 2024<\/td><td>22,40 $<\/td><td>%3,1 Art\u0131\u015f (pozitif deneme verileri)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Keros hisseleri klinik deneme g\u00fcncellemeleri ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131na dramatik \u015fekilde tepki verir. Pozitif s\u00fcrprizler gecede %15-20 hareketlere yol a\u00e7abilirken, hayal k\u0131r\u0131kl\u0131klar\u0131 genellikle keskin d\u00fczeltmelere neden olur. Anahtar nokta, bunun tipik bir blue-chip hisse senedi olmad\u0131\u011f\u0131d\u0131r\u2014t\u0131bbi inovasyona y\u00f6nelik y\u00fcksek riskli, y\u00fcksek \u00f6d\u00fcll\u00fc bir oyundur.<\/p> <h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h3> <p>Keros hisseleri olduk\u00e7a dalgal\u0131 bir seyir izledi:<\/p> <p><strong>Mart 2025<\/strong>: 18,20 $ (1. \u00e7eyrek sonras\u0131 iyimserlik)<br> <strong>Nisan 2025<\/strong>: 16,80 $ (genel piyasa geri \u00e7ekilmesi)<br> <strong>May\u0131s 2025<\/strong>: 14,50 $ (1. \u00e7eyrek gelir hayal k\u0131r\u0131kl\u0131\u011f\u0131)<br> <strong>Haziran 2025<\/strong>: 13,25 $ (sermaye geri d\u00f6n\u00fc\u015f\u00fc endi\u015feleri)<br> <strong>Temmuz 2025<\/strong>: 15,10 $ (Faz 3 deneme ba\u015flang\u0131c\u0131 deste\u011fi)<br> <strong>A\u011fustos 2025<\/strong>: 15,48 $ (2. \u00e7eyrek kazan\u00e7lar\u0131 beklentileri a\u015ft\u0131)<\/p> <p>Hisse senedi bu d\u00f6nemde yakla\u015f\u0131k <strong>%15<\/strong> de\u011fer kaybetti ancak son haftalarda istikrar i\u015faretleri g\u00f6sterdi. Neden bu volatilite? Keros, klinik deneme sonu\u00e7lar\u0131n\u0131n bir gecede \u015firket de\u011ferlemesini y\u00fckseltip d\u00fc\u015f\u00fcrebildi\u011fi, son derece \u00f6ng\u00f6r\u00fclemez biyoteknoloji sekt\u00f6r\u00fcnde faaliyet g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik ilerlemeye dayanarak, gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 22-28 $ (3. \u00e7eyrek sonu\u00e7lar\u0131 ve deneme g\u00fcncellemelerine ba\u011fl\u0131) \u2192 <strong>AL<\/strong><br> <strong>2026<\/strong>: 35-45 $ (\u00f6nc\u00fc adaylar i\u00e7in FDA ba\u015fvurular\u0131 potansiyeli)<br> <strong>2028<\/strong>: 60-80 $ (onaylar verilirse ticarile\u015fme a\u015famas\u0131)<br> <strong>2030<\/strong>: 100+ $ (yerle\u015fik nadir hastal\u0131k franchise\u2019\u0131)<\/p> <p><strong>Karar<\/strong>: Bu, risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>spek\u00fclatif bir al\u0131m<\/strong>. Klinik denemeler ba\u015far\u0131l\u0131 olursa potansiyel kazan\u00e7 \u00e7ok b\u00fcy\u00fck, ancak ba\u015far\u0131s\u0131zl\u0131k riski de \u00f6nemli. Yaln\u0131zca kaybetmeyi g\u00f6ze alabilece\u011finiz paray\u0131 ay\u0131r\u0131n.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: En b\u00fcy\u00fck risk\u2014Faz 3 denemeleri yetersiz etkinlik veya g\u00fcvenlik sorunlar\u0131 g\u00f6sterebilir. Biyoteknoloji hisseleri olumsuz deneme sonu\u00e7lar\u0131nda %50-80 d\u00fc\u015febilir.<\/li> <li><strong>D\u00fczenleyici Engeller<\/strong>: FDA reddi veya ek \u00e7al\u0131\u015fmalar talebi ticarile\u015fmeyi y\u0131llarca geciktirebilir.<\/li> <li><strong>Nakit T\u00fcketimi<\/strong>: Son sermaye geri d\u00f6n\u00fc\u015flerine ra\u011fmen, Keros pipeline geli\u015ftirmede nakit yakmaya devam ediyor. Muhtemelen ek finansman turlar\u0131 gerekecek.<\/li> <li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer TGF-\u03b2 inhibit\u00f6rleri geli\u015ftiriyor ve piyasaya ilk ula\u015fabilirler.<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Muhte\u015fem D\u00f6n\u00fc\u015f\u00fcm<\/strong>: Keros, 2025 1. \u00e7eyre\u011finde <strong>148,5 milyon $ net gelir<\/strong> bildirirken, 2024 1. \u00e7eyre\u011finde <strong>43,1 milyon $ zarar<\/strong> a\u00e7\u0131klam\u0131\u015ft\u0131\u2014tam bir finansal d\u00f6n\u00fc\u015f\u00fcm (<a href=\"https:\/\/www.marketbeat.com\/earnings\/reports\/2025-8-6-keros-therapeutics-inc-stock\/\">2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>).<\/li> <li><strong>Faz 3 \u0130lerlemesi<\/strong>: RENEW denemesinin ba\u015flat\u0131lmas\u0131 \u015firketin geli\u015ftirme takvimine uydu\u011funu g\u00f6steriyor.<\/li> <li><strong>Yetim \u0130la\u00e7 Stat\u00fcs\u00fc<\/strong>: KER-065, Duchenne Kas Distrofisi i\u00e7in bu de\u011ferli stat\u00fcy\u00fc ald\u0131, piyasa m\u00fcnhas\u0131rl\u0131\u011f\u0131 ve finansal avantajlar sa\u011fl\u0131yor.<\/li> <li><strong>Analist G\u00fcveni<\/strong>: Son volatiliteye ra\u011fmen, ortalama fiyat hedefi <strong>30,00 $<\/strong> civar\u0131nda\u2014mevcut fiyat\u0131n neredeyse iki kat\u0131 (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/KROS\/forecast\/\">Analist Tahminleri<\/a>).<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3\u2019\u00fcnden fazlas\u0131n\u0131 KROS\u2019a ay\u0131rmay\u0131n. Bu bir \"t\u00fcm \u00e7iftli\u011fi yat\u0131rma\" durumu de\u011fil.<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: T\u00fcm al\u0131m\u0131 tek seferde yapmak yerine, sat\u0131n almalar\u0131n\u0131z\u0131 birka\u00e7 aya yayarak zamanlama riskini azalt\u0131n.<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: Denemeler hayal k\u0131r\u0131kl\u0131\u011f\u0131 yarat\u0131rsa kendinizi %15-20 stop-loss ile koruyun.<\/li> <li><strong>Esprili Yakla\u015f\u0131m<\/strong>: \"KROS ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014i\u015fler yolunda gitti\u011finde inan\u0131lmaz heyecan verici, ama laboratuvarda beklenmedik patlamalara haz\u0131rl\u0131kl\u0131 olun!\"<\/li> <\/ol> <h2>\u2705 Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul komisyonlar sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>G\u00fcncel fiyat\u0131 ara\u015ft\u0131r\u0131n<\/td><td>Ger\u00e7ek zamanl\u0131 fiyat\u0131 15,48 $ olarak kontrol edin (30 A\u011fu 2025 itibar\u0131yla)<\/td><\/tr> <tr><td>4<\/td><td>Limit emri verin<\/td><td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>5<\/td><td>Pozisyonunuzu takip edin<\/td><td>Kazan\u00e7 tarihleri ve klinik deneme d\u00f6n\u00fcm noktalar\u0131n\u0131 izleyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Biyoteknoloji yat\u0131r\u0131mlar\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong>\u2014stratejileri b\u00fcy\u00fck risk olmadan test etmek i\u00e7in ideal<\/li> <li><strong>Herhangi tek bir belge ile y\u0131ld\u0131r\u0131m h\u0131z\u0131nda do\u011frulama<\/strong><\/li> <li><strong>Kripto ve e-c\u00fczdanlar dahil y\u00fczlerce para \u00e7ekme y\u00f6ntemi<\/strong><\/li> <li><strong>Karma\u015f\u0131k biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 eri\u015filebilir k\u0131lan kullan\u0131c\u0131 dostu platform<\/strong><\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, ba\u015flang\u0131\u00e7ta b\u00fcy\u00fck mebla\u011flar taahh\u00fct etmeden KROS gibi y\u00fcksek potansiyelli hisselere maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025\u2019te Keros Therapeutics: Hissenin Arkas\u0131ndaki Bilim<\/h2> <p>Keros Therapeutics sadece ba\u015fka bir biyoteknoloji \u015firketi de\u011fil\u2014t\u0131bb\u0131n en zorlu hastal\u0131klar\u0131 i\u00e7in tedaviler geli\u015ftiriyor. TGF-\u03b2 sinyal yollar\u0131na odaklanarak, kan h\u00fccresi \u00fcretimini etkileyen nadir hematolojik hastal\u0131klarla m\u00fccadele ediyorlar.<\/p> <p>\u015eirketin \u00f6nc\u00fc aday\u0131 KER-050, kemik ili\u011finin yeterince sa\u011fl\u0131kl\u0131 kan h\u00fccresi \u00fcretmedi\u011fi miyelodisplastik sendromlu hastalara yard\u0131mc\u0131 olmay\u0131 hedefliyor. Yakla\u015f\u0131mlar\u0131, bu hastal\u0131klar\u0131 geleneksel tedavilere k\u0131yasla temelden farkl\u0131 bir \u015fekilde ele al\u0131yor.<\/p> <p><strong>2025 e\u011flenceli bilgi<\/strong>: Keros\u2019un Lexington\u2019daki ara\u015ft\u0131rma laboratuvarlar\u0131nda o kadar hassas ekipmanlar var ki, ara\u015ft\u0131rmac\u0131lar\u0131n g\u00fc\u00e7l\u00fc parf\u00fcm veya kolonya kullanmaktan ka\u00e7\u0131nmalar\u0131 gerekiyor\u2014koku molek\u00fclleri deney sonu\u00e7lar\u0131n\u0131 etkileyebilir!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Keros Therapeutics Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>30 A\u011fustos 2025 itibar\u0131yla Keros Therapeutics, Inc. (KROS) <strong>15,48 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu fiyat hem de\u011fer avc\u0131lar\u0131n\u0131n hem de b\u00fcy\u00fcme yat\u0131r\u0131mc\u0131lar\u0131n\u0131n dikkatini \u00e7ekti. Ancak takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong> kesinlikle kritik. Keros, bu tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve tarihsel olarak bu raporlar hisse fiyat\u0131nda \u00f6nemli hareketlere neden oldu.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 KROS Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<p>Biyoteknoloji hisseleri gibi KROS i\u00e7in kazan\u00e7lar\u0131n neden bu kadar \u00f6nemli oldu\u011funu g\u00f6stereyim:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>14,32 $<\/td>\n<td>%8,1 Art\u0131\u015f (EPS tahminlerini a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>7 May 2025<\/td>\n<td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>16,50 $<\/td>\n<td>%12,3 D\u00fc\u015f\u00fc\u015f (gelir beklentisi kar\u015f\u0131lanmad\u0131)<\/td>\n<\/tr>\n<tr>\n<td>12 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Rapor<\/td>\n<td>18,75 $<\/td>\n<td>%4,2 Art\u0131\u015f (pipeline ilerlemesi)<\/td>\n<\/tr>\n<tr>\n<td>5 Kas 2024<\/td>\n<td>3. \u00c7eyrek 2024<\/td>\n<td>20,10 $<\/td>\n<td>%6,8 D\u00fc\u015f\u00fc\u015f (klinik gecikmeler)<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek 2024<\/td>\n<td>22,40 $<\/td>\n<td>%3,1 Art\u0131\u015f (pozitif deneme verileri)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Keros hisseleri klinik deneme g\u00fcncellemeleri ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131na dramatik \u015fekilde tepki verir. Pozitif s\u00fcrprizler gecede %15-20 hareketlere yol a\u00e7abilirken, hayal k\u0131r\u0131kl\u0131klar\u0131 genellikle keskin d\u00fczeltmelere neden olur. Anahtar nokta, bunun tipik bir blue-chip hisse senedi olmad\u0131\u011f\u0131d\u0131r\u2014t\u0131bbi inovasyona y\u00f6nelik y\u00fcksek riskli, y\u00fcksek \u00f6d\u00fcll\u00fc bir oyundur.<\/p>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h3>\n<p>Keros hisseleri olduk\u00e7a dalgal\u0131 bir seyir izledi:<\/p>\n<p><strong>Mart 2025<\/strong>: 18,20 $ (1. \u00e7eyrek sonras\u0131 iyimserlik)<br \/> <strong>Nisan 2025<\/strong>: 16,80 $ (genel piyasa geri \u00e7ekilmesi)<br \/> <strong>May\u0131s 2025<\/strong>: 14,50 $ (1. \u00e7eyrek gelir hayal k\u0131r\u0131kl\u0131\u011f\u0131)<br \/> <strong>Haziran 2025<\/strong>: 13,25 $ (sermaye geri d\u00f6n\u00fc\u015f\u00fc endi\u015feleri)<br \/> <strong>Temmuz 2025<\/strong>: 15,10 $ (Faz 3 deneme ba\u015flang\u0131c\u0131 deste\u011fi)<br \/> <strong>A\u011fustos 2025<\/strong>: 15,48 $ (2. \u00e7eyrek kazan\u00e7lar\u0131 beklentileri a\u015ft\u0131)<\/p>\n<p>Hisse senedi bu d\u00f6nemde yakla\u015f\u0131k <strong>%15<\/strong> de\u011fer kaybetti ancak son haftalarda istikrar i\u015faretleri g\u00f6sterdi. Neden bu volatilite? Keros, klinik deneme sonu\u00e7lar\u0131n\u0131n bir gecede \u015firket de\u011ferlemesini y\u00fckseltip d\u00fc\u015f\u00fcrebildi\u011fi, son derece \u00f6ng\u00f6r\u00fclemez biyoteknoloji sekt\u00f6r\u00fcnde faaliyet g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik ilerlemeye dayanarak, gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 22-28 $ (3. \u00e7eyrek sonu\u00e7lar\u0131 ve deneme g\u00fcncellemelerine ba\u011fl\u0131) \u2192 <strong>AL<\/strong><br \/> <strong>2026<\/strong>: 35-45 $ (\u00f6nc\u00fc adaylar i\u00e7in FDA ba\u015fvurular\u0131 potansiyeli)<br \/> <strong>2028<\/strong>: 60-80 $ (onaylar verilirse ticarile\u015fme a\u015famas\u0131)<br \/> <strong>2030<\/strong>: 100+ $ (yerle\u015fik nadir hastal\u0131k franchise\u2019\u0131)<\/p>\n<p><strong>Karar<\/strong>: Bu, risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>spek\u00fclatif bir al\u0131m<\/strong>. Klinik denemeler ba\u015far\u0131l\u0131 olursa potansiyel kazan\u00e7 \u00e7ok b\u00fcy\u00fck, ancak ba\u015far\u0131s\u0131zl\u0131k riski de \u00f6nemli. Yaln\u0131zca kaybetmeyi g\u00f6ze alabilece\u011finiz paray\u0131 ay\u0131r\u0131n.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: En b\u00fcy\u00fck risk\u2014Faz 3 denemeleri yetersiz etkinlik veya g\u00fcvenlik sorunlar\u0131 g\u00f6sterebilir. Biyoteknoloji hisseleri olumsuz deneme sonu\u00e7lar\u0131nda %50-80 d\u00fc\u015febilir.<\/li>\n<li><strong>D\u00fczenleyici Engeller<\/strong>: FDA reddi veya ek \u00e7al\u0131\u015fmalar talebi ticarile\u015fmeyi y\u0131llarca geciktirebilir.<\/li>\n<li><strong>Nakit T\u00fcketimi<\/strong>: Son sermaye geri d\u00f6n\u00fc\u015flerine ra\u011fmen, Keros pipeline geli\u015ftirmede nakit yakmaya devam ediyor. Muhtemelen ek finansman turlar\u0131 gerekecek.<\/li>\n<li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer TGF-\u03b2 inhibit\u00f6rleri geli\u015ftiriyor ve piyasaya ilk ula\u015fabilirler.<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Muhte\u015fem D\u00f6n\u00fc\u015f\u00fcm<\/strong>: Keros, 2025 1. \u00e7eyre\u011finde <strong>148,5 milyon $ net gelir<\/strong> bildirirken, 2024 1. \u00e7eyre\u011finde <strong>43,1 milyon $ zarar<\/strong> a\u00e7\u0131klam\u0131\u015ft\u0131\u2014tam bir finansal d\u00f6n\u00fc\u015f\u00fcm (<a href=\"https:\/\/www.marketbeat.com\/earnings\/reports\/2025-8-6-keros-therapeutics-inc-stock\/\">2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>).<\/li>\n<li><strong>Faz 3 \u0130lerlemesi<\/strong>: RENEW denemesinin ba\u015flat\u0131lmas\u0131 \u015firketin geli\u015ftirme takvimine uydu\u011funu g\u00f6steriyor.<\/li>\n<li><strong>Yetim \u0130la\u00e7 Stat\u00fcs\u00fc<\/strong>: KER-065, Duchenne Kas Distrofisi i\u00e7in bu de\u011ferli stat\u00fcy\u00fc ald\u0131, piyasa m\u00fcnhas\u0131rl\u0131\u011f\u0131 ve finansal avantajlar sa\u011fl\u0131yor.<\/li>\n<li><strong>Analist G\u00fcveni<\/strong>: Son volatiliteye ra\u011fmen, ortalama fiyat hedefi <strong>30,00 $<\/strong> civar\u0131nda\u2014mevcut fiyat\u0131n neredeyse iki kat\u0131 (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/KROS\/forecast\/\">Analist Tahminleri<\/a>).<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3\u2019\u00fcnden fazlas\u0131n\u0131 KROS\u2019a ay\u0131rmay\u0131n. Bu bir &#8220;t\u00fcm \u00e7iftli\u011fi yat\u0131rma&#8221; durumu de\u011fil.<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: T\u00fcm al\u0131m\u0131 tek seferde yapmak yerine, sat\u0131n almalar\u0131n\u0131z\u0131 birka\u00e7 aya yayarak zamanlama riskini azalt\u0131n.<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: Denemeler hayal k\u0131r\u0131kl\u0131\u011f\u0131 yarat\u0131rsa kendinizi %15-20 stop-loss ile koruyun.<\/li>\n<li><strong>Esprili Yakla\u015f\u0131m<\/strong>: &#8220;KROS ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014i\u015fler yolunda gitti\u011finde inan\u0131lmaz heyecan verici, ama laboratuvarda beklenmedik patlamalara haz\u0131rl\u0131kl\u0131 olun!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul komisyonlar sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>G\u00fcncel fiyat\u0131 ara\u015ft\u0131r\u0131n<\/td>\n<td>Ger\u00e7ek zamanl\u0131 fiyat\u0131 15,48 $ olarak kontrol edin (30 A\u011fu 2025 itibar\u0131yla)<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit emri verin<\/td>\n<td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Pozisyonunuzu takip edin<\/td>\n<td>Kazan\u00e7 tarihleri ve klinik deneme d\u00f6n\u00fcm noktalar\u0131n\u0131 izleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Biyoteknoloji yat\u0131r\u0131mlar\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong>\u2014stratejileri b\u00fcy\u00fck risk olmadan test etmek i\u00e7in ideal<\/li>\n<li><strong>Herhangi tek bir belge ile y\u0131ld\u0131r\u0131m h\u0131z\u0131nda do\u011frulama<\/strong><\/li>\n<li><strong>Kripto ve e-c\u00fczdanlar dahil y\u00fczlerce para \u00e7ekme y\u00f6ntemi<\/strong><\/li>\n<li><strong>Karma\u015f\u0131k biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 eri\u015filebilir k\u0131lan kullan\u0131c\u0131 dostu platform<\/strong><\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, ba\u015flang\u0131\u00e7ta b\u00fcy\u00fck mebla\u011flar taahh\u00fct etmeden KROS gibi y\u00fcksek potansiyelli hisselere maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025\u2019te Keros Therapeutics: Hissenin Arkas\u0131ndaki Bilim<\/h2>\n<p>Keros Therapeutics sadece ba\u015fka bir biyoteknoloji \u015firketi de\u011fil\u2014t\u0131bb\u0131n en zorlu hastal\u0131klar\u0131 i\u00e7in tedaviler geli\u015ftiriyor. TGF-\u03b2 sinyal yollar\u0131na odaklanarak, kan h\u00fccresi \u00fcretimini etkileyen nadir hematolojik hastal\u0131klarla m\u00fccadele ediyorlar.<\/p>\n<p>\u015eirketin \u00f6nc\u00fc aday\u0131 KER-050, kemik ili\u011finin yeterince sa\u011fl\u0131kl\u0131 kan h\u00fccresi \u00fcretmedi\u011fi miyelodisplastik sendromlu hastalara yard\u0131mc\u0131 olmay\u0131 hedefliyor. Yakla\u015f\u0131mlar\u0131, bu hastal\u0131klar\u0131 geleneksel tedavilere k\u0131yasla temelden farkl\u0131 bir \u015fekilde ele al\u0131yor.<\/p>\n<p><strong>2025 e\u011flenceli bilgi<\/strong>: Keros\u2019un Lexington\u2019daki ara\u015ft\u0131rma laboratuvarlar\u0131nda o kadar hassas ekipmanlar var ki, ara\u015ft\u0131rmac\u0131lar\u0131n g\u00fc\u00e7l\u00fc parf\u00fcm veya kolonya kullanmaktan ka\u00e7\u0131nmalar\u0131 gerekiyor\u2014koku molek\u00fclleri deney sonu\u00e7lar\u0131n\u0131 etkileyebilir!<\/p>\n"},"faq":[{"question":"Keros Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Keros Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden al\u0131m yapabilirsiniz."},{"question":"Keros Therapeutics hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz platforma ba\u011fl\u0131d\u0131r. Pocket Option gibi baz\u0131 platformlarda minimum depozito 5 $\u2019d\u0131r."},{"question":"Keros Therapeutics hisseleri ne kadar risklidir?","answer":"Biyoteknoloji hisseleri genellikle y\u00fcksek volatiliteye sahiptir ve klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 olarak b\u00fcy\u00fck fiyat dalgalanmalar\u0131 ya\u015fayabilir. Bu nedenle riskli yat\u0131r\u0131mlar aras\u0131nda yer al\u0131r."},{"question":"Keros Therapeutics\u2019in klinik denemeleri neden \u00f6nemlidir?","answer":"Klinik denemeler \u015firketin ila\u00e7 adaylar\u0131n\u0131n etkinli\u011fi ve g\u00fcvenli\u011fi hakk\u0131nda bilgi verir. Ba\u015far\u0131l\u0131 denemeler hisse fiyat\u0131n\u0131 olumlu etkilerken, ba\u015far\u0131s\u0131zl\u0131klar ciddi de\u011fer kay\u0131plar\u0131na yol a\u00e7abilir."},{"question":"Yeni ba\u015flayan biri Keros Therapeutics hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss emirleri kullanarak riskinizi y\u00f6netin ve yaln\u0131zca kaybetmeyi g\u00f6ze alabilece\u011finiz miktarda yat\u0131r\u0131m yap\u0131n."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Keros Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Keros Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden al\u0131m yapabilirsiniz."},{"question":"Keros Therapeutics hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz platforma ba\u011fl\u0131d\u0131r. Pocket Option gibi baz\u0131 platformlarda minimum depozito 5 $\u2019d\u0131r."},{"question":"Keros Therapeutics hisseleri ne kadar risklidir?","answer":"Biyoteknoloji hisseleri genellikle y\u00fcksek volatiliteye sahiptir ve klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 olarak b\u00fcy\u00fck fiyat dalgalanmalar\u0131 ya\u015fayabilir. Bu nedenle riskli yat\u0131r\u0131mlar aras\u0131nda yer al\u0131r."},{"question":"Keros Therapeutics\u2019in klinik denemeleri neden \u00f6nemlidir?","answer":"Klinik denemeler \u015firketin ila\u00e7 adaylar\u0131n\u0131n etkinli\u011fi ve g\u00fcvenli\u011fi hakk\u0131nda bilgi verir. Ba\u015far\u0131l\u0131 denemeler hisse fiyat\u0131n\u0131 olumlu etkilerken, ba\u015far\u0131s\u0131zl\u0131klar ciddi de\u011fer kay\u0131plar\u0131na yol a\u00e7abilir."},{"question":"Yeni ba\u015flayan biri Keros Therapeutics hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss emirleri kullanarak riskinizi y\u00f6netin ve yaln\u0131zca kaybetmeyi g\u00f6ze alabilece\u011finiz miktarda yat\u0131r\u0131m yap\u0131n."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-30T14:06:13+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-30T14:06:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/\",\"name\":\"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"datePublished\":\"2025-08-30T14:06:13+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-30T14:06:13+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-30T14:06:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/","name":"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","datePublished":"2025-08-30T14:06:13+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-keros-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Keros Therapeutics, Inc. (KROS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Keros Therapeutics, Inc. (KROS) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":360339,"slug":"how-to-buy-keros-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Keros Therapeutics, Inc. (KROS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Keros Therapeutics, Inc. (KROS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-keros-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":360336,"slug":"how-to-buy-keros-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Keros Therapeutics, Inc. (KROS) - Investimento em a\u00e7\u00f5es da Keros Therapeutics, Inc. (KROS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-keros-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/360340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=360340"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/360340\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334036"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=360340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=360340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=360340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}